Review Article

Prognostic Value of Circular RNA ciRS-7 in Various Cancers: A PRISMA-Compliant Meta-Analysis

Guangwei Tian,1 Guang Li,1 Lin Guan,2 Zihui Wang,3 and Nan Li1

1Department of Radiation Oncology, The First Affiliated Hospital of China Medical University, Shenyang 110001, China
2Department of Gastrointestinal, The First Affiliated Hospital of China Medical University, Shenyang 110001, China
3Department of Neuroscience, Cleveland Clinic, Cleveland, OH 44106, USA

Correspondence should be addressed to Nan Li; linankeyan@126.com

Received 31 July 2019; Revised 27 December 2019; Accepted 31 December 2019; Published 23 January 2020

Academic Editor: Rosario Caltabiano

Copyright © 2020 Guangwei Tian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Circular RNAs (circRNAs) have been shown to be involved in tumorigenesis. As a member of circRNAs, ciRS-7 is thought to be a negative prognostic indicator in multiple types of cancer. The present study aimed to comprehensively explore the value of ciRS-7 in tumor malignancy. Materials and Methods. A systematic review of PubMed, Web of Science, and the Cochrane library was carried out to examine the related studies. The pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated from the available publications by STATA 12.0. Subgroup analysis, publication bias, sensitivity analysis, and meta-regression were conducted. Results. This meta-analysis included 1,714 patients from 13 cohorts. The results suggested that high ciRS-7 expression was significantly associated with overall survival (OS) (HR = 2.17, 95% CI = 1.50–3.15, P < 0.001) in various cancers. Stratified analyses indicated that elevated levels of ciRS-7 appeared to be a powerful prognostic biomarker for patients with non-small-cell lung cancer (NSCLC) (HR: 2.50, 95% CI: 1.07–6.07, P = 0.035), colorectal cancer (CRC) (HR: 1.95, 95% CI: 1.34–2.84, P < 0.001), and gastric cancer (GC) (HR: 2.32, 95% CI: 1.48–3.64, P < 0.001). A similar effect was also observed in subgroup of sample size, analysis method, and cutoff value, except for ethnicity. The increased ciRS-7 expression was associated with a higher tumor stage (OR = 2.30, 95% CI: 1.69–3.13, P < 0.001). Conclusions. High expression of ciRS-7 has a significant correlation with the high stage in various cancers, and ciRS-7 is intimately associated with an adverse OS in numerous cancers. Thus, ciRS-7 may act as a potential biomarker for the development of malignancies.

1. Introduction

Circular RNAs are a type of noncoding RNAs that have a unique single-stranded closed ring structure, which were discovered in viroid via electron microscopy as early as in 1976, and originally thought to be that with incorrect splicing of RNA [1, 2]. Researchers have been focusing on circRNAs since the application of high-throughput RNA sequencing and bioinformatics analyses, and thousands of human circRNAs have been identified so far [3, 4].

Recently, a lot of studies have confirmed a functional role played by circRNAs in cancer, which is circRNAs could be involved in tumor proliferation, angiogenesis [5], invasion, and metastasis [6]. Furthermore, evidence has showed that circRNAs could regulate most critical signaling pathways in cancer including Wnt [7], PI3K/AKT [8], and MAPK/ERK [9] pathways and deregulated expression of circRNAs in many types of cancers, including GC [10], bladder cancer [11], breast cancer [12], colorectal cancer [13], lung cancer [14], and so on.

ciRS-7, also known as the antisense to the cerebellar degeneration-related protein 1 transcript (CDR1as), is one of the circRNAs specifically binding to human microRNA-7 (miR-7) as a sponge [15, 16]. Currently, ciRS-7 has received increasing attention and became one of the most extensively studied circRNAs in cancer. In MiOncoCirc dataset, ciRS-7 (CDR1-AS) is classified into the ubiquitous category and expressed in 19 types of cancer [17]. The upregulated expression of ciRS-7 is found in several cancers and contributes to the development of several cancers, including...
non-small-cell lung cancer (NSCLC) [18], colorectal cancer (CRC) [19], and hepatocellular carcinoma (HCC) [20]. Besides, ciRS-7 participates in many critical cancer-related pathways, such as EGFR [21, 22], PTEN/P3K/AKT [23], and NF-kB [24, 25]. Furthermore, increasing evidences suggest that ciRS-7 is closely related to the prognosis and clinicopathological features of cancers [18, 19, 21–30]; however, the prognostic results remain inconsistent. Thus, we conducted this meta-analysis to achieve a precise evaluation of the prognostic value of ciRS-7 in cancer patients.

2. Materials and Methods

This meta-analysis was performed by following the PRISMA guidelines [31]. Systematic literature research was independently performed by two authors through electronic databases, including PubMed, Web of Science, and the Cochrane Library for eligible studies published until March 18, 2019. Studies were selected using the following terms: “CDR1-AS” or “cdr1as” or “ciRS-7” and “tumor” or “cancer” or “carcinoma”. Citation lists of review articles were manually searched for finding potentially eligible studies.

2.1. Study Selection. Two authors (Guangwei Tian and Lin Guan) independently evaluated all of the included studies, and any disagreement was resolved by consultation with the supervisor (Nan Li). The following inclusion criteria were considered: (a) studies investigating on patients with any type of cancers; (b) studies in which the patients were grouped by the expression of ciRS-7 via validating techniques; (c) studies reporting the sufficient information association between ciRS-7 expression and survival, in which the hazard ratio (HR) with 95% confidence interval (95% CI); (d) studies reporting the relationship between ciRS-7 expression and clinical stage of cancer patients. Exclusion criteria were as follows: (a) studies without sufficient or usable data; (b) duplicative publications; (c) reviews, case reports, editorials, and conference abstracts; (d) laboratory studies only investigating the molecular function of ciRS-7.

2.2. Data Extraction and Quality Assessment. The primary outcome used in this meta-analysis was overall survival. The secondary outcome was clinical stage. The following information was extracted from each study: first author name, year, country, tumor type, sample size and type, expression of ciRS-7, detection technique, follow-up duration, and HRs of ciRS-7 expression for overall survival (OS) with 95% CIs. In all the articles included in our study, the expression of ciRS-7 was detected in tumor tissues. The Newcastle–Ottawa Score (NOS) quality assessment system adopted for case-control studies was utilized to examine the methodological quality of studies [32]. Included studies were scored according to three broad perspectives, selection, comparability, and exposure, through the star scoring method with a range of lowest quality (0 star) to the highest quality (9 stars). A score of ≥6 indicated high quality [33].

2.3. Statistical Analysis. Meta-analysis was performed using Stata 12.0 software (Stata, College Station, TX, USA). The prognostic value of ciRS-7 expression in patients with various types of cancers was analyzed by the pooled HR associated with the 95% CI. If the HR and 95% CI were not directly reported, we extracted them from Kaplan–Meier curves [34]. ORs were extracted for evaluating the association between the expression of ciRS-7 and tumor stage. Higgins $I^2$ statistic was performed for evaluating the heterogeneity [35]. If heterogeneity was present ($I^2 > 50$% or $P < 0.05$), a random-effect model was applied [36]; otherwise, a fixed effect model was used [37]. Publication bias was conducted by Begg’s test [38]. Sensitivity was also performed to identify the effect of the individual study data on summary for HRs and ORs.

3. Results

3.1. Characteristics of Studies. There were 85 studies from a database search, and 74 irrelevant studies and duplicates were excluded after reviewing the titles and abstracts. On the basis of the inclusion and exclusion criteria, ultimately, 13 cohorts from 11 studies and 1,714 patients were included in this meta-analysis. A flowchart of the studies screening process is shown in Figure 1, and the detailed characteristics are summarized in Table 1. The enrolled studies were published in 2017 and 2018. The countries represented in the studies included China, Japan, and the Netherlands. Among these 13 cohorts, there were 7 types of cancers in the meta-analysis (3 NSCLC [18, 22, 24], 3 CRC [19, 21, 2], 2 GC [23, 1] breast cancer [2], 2 esophageal squamous cell cancer (ESCC) [25, 29], 1 laryngeal squamous cell cancer (LSCC) [28], and 1 cholangiocarcinoma (CAA) [26]). ciRS-7 expression was measured in cancerous tissue by quantitative real-time PCR in all cohorts. Among 13 cohorts, 12 cohorts from 10 studies assessed the correlation between ciRS-7 and prognosis in various tumors [18, 19, 21–24, 26–29], and 6 cohorts from 5 studies reported the relationship between ciRS-7 and tumor stage [19, 22, 24, 29, 30]. HR and corresponding 95% CIs were extracted from the survival curve in one study. All included cohorts’ NOS scores were ≥6 (Table 1).

3.2. Association between ciRS-7 and Overall Survival. In a pooled analysis of 12 cohorts, including 1,628 cancer patients [18, 19, 21-24, 26-29], the results indicated that high expression of ciRS-7 was significantly associated with poor OS (Figure 2). Due to a significant heterogeneity ($I^2 = 85.6, P < 0.001$), the random-effects model was used. The combined HR was 2.17 (95% CI: 1.50–3.15, $P < 0.001$). After stratified by ethnicity, we found an increased ciRS-7 which predicted a worse OS for Asians (HR: 2.35, 95% CI: 1.78–3.11, $P < 0.001$), but not for Caucasians (HR: 1.03, 95% CI: 0.90–1.17, $P = 0.659$).
When we regarded the sample size, analysis method, and different cutoff values, there was no significant change for pooled HR in each subgroup (Table 2). Due to significant heterogeneity in analysis, we detected the source of heterogeneity by multivariate meta-regression analysis. It was found that sample size ($P = 0.066$), cancer type ($P = 0.860$), ethnicity ($P = 0.111$), analysis method ($P = 0.772$), cutoff value ($P = 0.208$), and study design ($P = 0.924$) were not the sources of heterogeneity (Table 2).

A sensitivity analysis was conducted to assess whether one study would affect the overall results and to confirm the stability of results. In Figure 3, the results were relatively stable. The funnel plot was asymmetry (Figure 4). Additionally, Begg’s test was used for quantitative analysis, and $P$ value was 0.115, which indicated no publication bias in this meta-analysis.

3.3. Association between ciRS-7 and Clinical Stage. 6 cohorts from 5 studies comprising 715 patients provided valid data for the correlation between ciRS-7 and clinical stage [19, 22, 24, 29, 30]. Among these 6 cohorts, there were 3 types of cancers (2 CRC, 2 NSCLC, and 2 ESCC). The result showed that an increased ciRS-7 expression was associated with a higher clinical stage (OR = 2.30, 95% CI: 1.69–3.13, $P < 0.001$). Cancer type by subgroup analysis indicated that the positive correlation between ciRS-7 and clinical stage was found in CRC, NSCLC, and ESCC (Figure 5). Significant heterogeneity was not observed in this statistic due to $I^2 = 40.6\%$. Begg’s test was performed, and no significant publication bias was found for the clinical stage ($P = 1.000$) (Figure 6). Sensitivity analysis was performed through the sequential omission of every single publication, and the results were not significantly altered (Figure 7).

4. Discussion

Despite the advancement in treatment modalities, cancer is still one of the leading causes of death worldwide. It is estimated that there will be 22.2 million new cancer cases in 184 countries by 2030 [39]. Therefore, novel biological-specific biomarkers are urgently needed for cancer early detection. Besides prognosis, biomarker is an important priority, which can affect clinical decision-making and the overall results.

Increasing evidence demonstrated that circRNAs are attractive candidates for diagnostic and prognostic biomarkers [40, 41], and among them, ciRS-7 stands out as an oncogenic circRNA at least for a subset of cancer types. Meanwhile, in some studies, ciRS-7 also exerts anti-oncogenic functions [42, 43]. Although researches on ciRS-7 develop fast, the prognostic role of ciRS-7 in cancer is still uncertain. For that reason, the study was conducted, and to our knowledge, no meta-analyses evaluated the correlation...
Table 1: Characteristics of studies included in this meta-analysis.

| Authors            | Country | Type of sample | Study design | Type of cancer | Expression of ciRS-7 | Cutoff value | Sample size | NOS score | Follow-up | HR (95% CI) for OS | Detection method | Analysis method |
|--------------------|---------|----------------|--------------|----------------|---------------------|--------------|-------------|-----------|-----------|-------------------|------------------|-----------------|
| Jiang et al. [26]  | China   | Tissue         | Retrospective| CCA            | Upregulation        | NR           | 54          | 6         | NR        | 1.887 (1.025–3.474) | qRT-PCR           | M               |
| Weng et al.        | China   | Tissue         | Retrospective| CRC            | Upregulation        | Median       | 153         | 8         | 3.7y-median| 1.8689 (1.0977–3.9023) | qRT-PCR           | M               |
| Weng et al.        | Japan   | Tissue         | Retrospective| CRC            | Upregulation        | Median       | 165         | 8         | 5.1y-median| 2.7262 (1.0879–6.8315) | qRT-PCR           | M               |
| Tang et al. [21]   | China   | Tissue         | Retrospective| CRC            | Upregulation        | Median       | 182         | 6         | NR        | 1.799 (1.055–3.068) | qRT-PCR           | U               |
| Pan et al.         | China   | Tissue         | Prospective  | GC             | Upregulation        | Median       | 102         | 6         | NR        | 2.11 (1.1610–3.8348) | qRT-PCR           | U               |
| Pan et al.         | China   | Tissue         | Prospective  | GC             | Upregulation        | Median       | 154         | 6         | NR        | 2.63 (1.3177–5.2493) | qRT-PCR           | U               |
| Su et al. [24]     | China   | Tissue         | Retrospective| NSCLC          | Upregulation        | Mean         | 128         | 6         | NR        | 1.705 (1.02–2.86) | qRT-PCR           | M               |
| Zhang et al. [22]  | China   | Tissue         | Retrospective| NSCLC          | Upregulation        | Median       | 60          | 7         | NR        | 6.132 (2.923–7.556) | qRT-PCR           | M               |
| Li et al. [29]     | China   | Tissue         | Retrospective| ESCC           | Upregulation        | Median       | 123         | 7         | NR        | 2.70 (1.55–4.71) | qRT-PCR           | U               |
| Uhr et al. [27]    | Netherlands | Tissue       | Retrospective| BC             | Upregulation        | Median       | 345         | 8         | 91y-median| 1.03 (0.90–1.17) | qRT-PCR           | U               |
| Yan et al. [18]    | China   | Tissue         | Retrospective| NSCLC          | Upregulation        | Median       | 132         | 8         | 46y-median| 1.575 (1.016–2.440) | qRT-PCR           | M               |
| Zhang J et al. [28]| China   | Tissue         | Retrospective| LSCC           | Upregulation        | NR           | 30          | 6         | NR        | 4.026 (1.144–14.178) | qRT-PCR           | U               |
| Sang et al.        | China   | Tissue         | Retrospective| ESCC           | Upregulation        | Median       | 86          | NR        | NR        | qRT-PCR           | qRT-PCR           | NR              |

CCA, cholangiocarcinoma; CRC, colorectal cancer; GC, gastric cancer; NSCLC, non-small-cell lung cancer; BC, breast cancer; LSCC, laryngeal squamous cell carcinoma; ESCC, esophageal squamous cell carcinoma; NR, not reported; qRT-PCR, quantitative real-time-PCR; U, univariate analysis; M, multivariate analysis; *the study only reporting the association between ciRS-7 expression and tumor stage, no survival data; **HR and corresponding 95% CIs were extracted from the survival curve; ***compared with the normal tissue.
of ciRS-7 with the prognosis/clinical stages in numerous cancer patients. In this study, we combined the outcomes of 1,628 patients from 12 available cohorts, indicating that high expression of ciRS-7 was significantly associated with worse survival. In stratified analysis, the results showed that upregulated ciRS-7 predicted worse OS in NSCLC, CRC, and GC. Furthermore, a high level of ciRS-7 was significantly correlated with higher tumor stage in CRC, NSCLC, and ESCC. Sensitivity analysis showed that our results were stable. Importantly, it should be considered that significant heterogeneity was observed in the overall analysis. To find the heterogeneity, a meta-regression was performed and it indicated that sample size might be a contributing factor; yet, there might be other factors that could influence heterogeneity; unfortunately, studies included did not provide individual patient data.

### Table 2: Results of subgroup meta-analysis and meta-regression analysis.

| Subgroup | No. of studies | No. of patients | Random-effects model | Heterogeneity | Meta-regression |
|----------|----------------|----------------|----------------------|---------------|----------------|
|          |                |                | HR (95% CI)          | P value       | Ph | I² (%) | P value |
| **Cancer type** |  | | | | | | |
| NSCLC | 3 | 320 | 2.50 (1.07–6.07) | 0.035 | <0.001 | 90 |
| CRC | 3 | 500 | 1.95 (1.34–2.84) | <0.001 | 0.735 | 0 |
| GC | 2 | 256 | 2.32 (1.48–3.64) | <0.001 | 0.636 | 0 |
| Others | 4 | 552 | 1.90 (1.00–3.61) | 0.05 | <0.001 | 83.3 |
| **Ethnicity** |  | | | | | | |
| Asian | 11 | 1283 | 2.35 (1.17–3.11) | <0.001 | 0.009 | 57.6 |
| Caucasian | 1 | 345 | 1.03 (0.90–1.17) | 0.659 | | |
| **Sample size** |  | | | | | | |
| ≥100 | 9 | 1484 | 1.83 (1.33–2.50) | <0.001 | <0.001 | 74.8 |
| <100 | 3 | 144 | 3.60 (1.52–8.52) | 0.004 | 0.012 | 77.6 |
| **Analysis method** |  | | | | | | |
| Univariable | 6 | 936 | 2.00 (1.23–3.25) | 0.005 | <0.001 | 81.8 |
| Multivariable | 6 | 692 | 2.32 (1.44–3.76) | 0.001 | 0.001 | 76.7 |
| **Cut-off value** |  | | | | | | |
| Median | 9 | 1416 | 2.19 (1.39–3.45) | 0.001 | <0.001 | 88.9 |
| Mean and others | 3 | 212 | 1.91 (1.31–2.79) | 0.001 | 0.464 | 0 |
| **Study design** |  | | | | | | |
| Retrospective | 10 | 1372 | 2.14 (1.41–3.26) | <0.001 | <0.001 | 87.3 |
| Prospective | 2 | 256 | 2.32 (1.48–3.64) | <0.001 | 0.636 | 0 |

NSCLC, non-small-cell lung cancer; CRC, colorectal cancer; GC, gastric cancer; Ph, the P value of Q test for heterogeneity test.
In subgroup analysis, ciRS-7 showed inconsistent prognostic effects in different cancer types. In NSCLC, CRC, and GC, high expression of ciRS-7 was found to be associated with worse prognosis. While in ‘others’ subgroup comprising ESCC, BC, LSCC, and CAA, the number of studies for each cancer type was only one, and the result showed HR = 1.90 (1.00–3.61), P = 0.05; therefore, we cannot reach a conclusion statistically that ciRS-7 has a role in predicting in this group. More studies are needed for credible conclusion for these four cancer types.

In subgroup analysis, ciRS-7 showed inconsistent prognostic effects in different cancer types. In NSCLC, CRC, and GC, high expression of ciRS-7 was found to be associated with worse prognosis. While in “others” subgroup comprising ESCC, BC, LSCC, and CAA, the number of studies for each cancer type was only one, and the result showed HR = 1.90 (1.00–3.61), P = 0.05; therefore, we cannot reach a conclusion statistically that ciRS-7 has a role in predicting in this group. More studies are needed for credible conclusion for these four cancer types. The ethnic difference in cancer has been identified and investigated in many studies [44–46]. As is the case with cancer type, no significant association was observed between ciRS-7 expression and Caucasian populations due to small sample size, which may be buttressed by meta-regression. According to the results of meta-regression, we found that sample size is most likely to be the greatest impact on heterogeneity among all factors, because although P value of the sample size is 0.066, it is the lowest among all the factors.

To understand the prognostic role of ciRS-7, the regulatory mechanism network of ciRS-7 in cancer needs to be considered. As a competing endogenous RNA, ciRS-7 is ∼1,500 nucleotides in length [47], and the ciRS-7/miR-7 axis should be the major mechanism for the reason that ciRS-7 possesses 73 conventional binding sites [15]. To be noted, many studies indicate a tumor-suppressive role for miR-7, and its downregulation is correlated with poor prognosis in cancer patients [48–50]. Studies have confirmed that miR-7 also directly targets insulin-like growth factor 1 receptor (IGF1R) [53], FAK [54], and PAK1 [55], which can inhibit the proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) of tumor cells. Recent studies show that, as a strong sponge for miR-7, ciRS-7 overexpression is found in GC [23], CRC [21], NSCLC [22], ESCC [30], and CAA [26]. Besides, ciRS-7 can abrogate the tumor-suppressive effect of miR-7 via different cancer-associated signaling pathways including EGFR [21, 22], PTEN/PI3K/AKT [23], NF-κB [24, 25], and IGF1R [21]. Taken together, the prognostic role of ciRS-7 in various cancer could be well explained.

With the closed ring structure, circRNAs are more stable, not easy to be degraded by RNase and high abundance than mRNA [56], which make circRNAs have more advantages in the development and application as a new clinical diagnostic marker. In view of the current researches, there are many prospects for the clinical application of ciRS-7. Recent studies found that circRNAs can be detected in blood and exosomes of cancer patients [57–59].
future, it will better reflect its clinical application value, if ciRS-7 can be detected in a noninvasive way. Furthermore, ciRS-7 is expected to become an emerging drug’s target. Studies show ciRS-7 overexpression can activate the EGFR pathway, which is one of the most important targets of NSCLC, to induce tumor cell growth [21, 22]. These findings will provide new opportunities for ciRS-7 to be developed as a targeted drug in the future.

Several limitations in this study should be carefully considered. Firstly, the number of included studies was limited which may weaken the power of the results. Secondly, not all different factors were analyzed in this meta-analysis because it was literature-based, and we only got the summarized data rather than individual patient data. Thirdly, some studies had not reported the cutoff values of ciRS-7, and there was no consensus for calculating the cutoff value. Fourthly, we extracted HR and 95% CI from the survival curve rather than directly from the original study for one study, which might impact the results. Finally, although publication biases on OS and clinical stage were not found by Begg’s test, there may be an underlying publication bias as studies with positive results could be more likely to be published than those with negative results. Therefore, our meta-analysis still needs further investigation.

In conclusion, this meta-analysis showed that upregulation of ciRS-7 is associated with adverse survival and higher clinical stage in multiple types of cancers. ciRS-7 may be a new star of the future drug target for fighting against

| Study ID          | OR (95% CI) | % weight |
|-------------------|-------------|----------|
| CRC               |             |          |
| Weng et al. -training cohort | 1.15 (0.58, 2.26) | 29.19    |
| Weng et al. -validation cohort | 3.75 (1.97, 7.16) | 17.66    |
| Subtotal (I-squared = 83.8%, p = 0.013) | 2.13 (1.35, 3.37) | 46.85    |
| NSCLC             |             |          |
| Su et al.         | 2.46 (1.16, 5.21) | 16.57    |
| Zhang X et al.    | 5.31 (1.64, 17.18) | 4.34     |
| Subtotal (I-squared = 14.7%, p = 0.279) | 3.06 (1.63, 5.74) | 20.91    |
| ESCC              |             |          |
| Li et al.         | 2.13 (1.04, 4.38) | 18.91    |
| Sang et al.       | 1.98 (0.82, 4.74) | 13.33    |
| Subtotal (I-squared = 0.0%, p = 0.897) | 2.07 (1.19, 3.60) | 32.24    |
| Overall (I-squared = 40.6%, p = 0.135) | 2.30 (1.69, 3.13) | 100.00   |

Figure 5: Forest plot for the association between ciRS-7 expression and tumor stage in various cancers.

Figure 6: Sensitivity analysis between ciRS-7 expression and clinical stage.
tumor growth or used as a biomarker for predicting the prognosis of cancer patients. Larger sample sizes and well-designed studies are needed in the future.

Conflicts of Interest
The authors report no conflicts of interest in this work.

Authors’ Contributions
Nan Li and Guang Li designed the study, Guangwei Tian and Lin Guan performed the Statistics. Nan Li and Guangwei Tian wrote the paper. Zihui Wang edited the manuscript.

Acknowledgments
The funding for this study was provided by the Wu Jieping Medical Foundation Special Fund for Clinical Research, China (320.6750.17116).

References
[1] H. L. Sanger, G. Klotz, D. Riesner, H. J. Gross, and A. K. Kleinschmidt, “Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures,” Proceedings of the National Academy of Sciences, vol. 73, no. 11, pp. 3852–3856, 1976.
[2] D. Kolakofsky, “Isolation and characterization of Sendai virus DI-RNAs,” Cell, vol. 8, no. 4, pp. 547–555, 1976.
[3] S. Memczak, M. Jens, A. Elefsinioti et al., “Circular RNAs are a large class of animal RNAs with regulatory potency,” Nature, vol. 495, no. 7441, pp. 333–338, 2013.
[4] L. Szabo and J. Salzman, “Detecting circular RNAs: bioinformatic and experimental challenges,” Nature Reviews Genetics, vol. 17, no. 11, pp. 679–692, 2016.
[5] D. Barbagallo, A. Caponnetto, D. Brix et al., “CircSMARCA5 regulates VEGFA mRNA splicing and angiogenesis in glioblastoma multiforme through the binding of SRSF1,” Cancers, vol. 11, no. 2, p. 194, 2019.
[6] D.-H. Bach, S. K. Lee, and A. K. Sood, “Circular RNAs in cancer,” Molecular Therapy-Nucleic Acids, vol. 16, pp. 118–129, 2019.
[7] L. Wan, L. Zhang, K. Fan, Z. X. Cheng, Q. C. Sun, and J. J. Wang, “Circular RNA-ITCH suppresses lung cancer proliferation via inhibiting the wnt/β-catenin pathway,” BioMed Research International, vol. 2016, Article ID 1579490, 11 pages, 2016.
[8] H. Zheng, T. Chen, C. Li et al., “A circular RNA hsa_circ_0079929 inhibits tumor growth in hepatocellular carcinoma,” Cancer Management and Research, vol. 11, pp. 443–454, 2019.
[9] D. Gao, X. Qi, X. Zhang, K. Fang, Z. Guo, and L. Li, “hsa_circRNA_006528 as a competing endogenous RNA promotes human breast cancer progression by sponging miR-7-5p and activating the MAPK/ERK signaling pathway,” Molecular Carcinogenesis, vol. 58, no. 4, pp. 554–564, 2019.
[10] P. Li, H. Chen, S. Chen et al., “Circular RNA 0000096 affects cell growth and migration in gastric cancer,” British Journal of Cancer, vol. 116, no. 5, pp. 626–633, 2017.
[11] C. Yang, W. Yuan, X. Yang et al., “Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17/miR-224 and regulating p21, PTEN expression,” Molecular Cancer, vol. 17, no. 1, p. 19, 2018.
prognosis and prediction of 1(st)-line tamoxifen therapy in breast cancer," *Scientific Reports*, vol. 8, no. 1, p. 9657, 2018.

[28] J. Zhang, H. Hu, Y. Zhao, and Y. Zhao, "CDR1as is over-expressed in laryngeal squamous cell carcinoma to promote the tumour’s progression via miR-7 signals," *Cell Prolifera-
tion*, vol. 51, no. 6, Article ID e12521, 2018.

[29] R.-C. Li, S. Ke, F.-F. Meng et al., "CIRS-7 promotes growth and metastasis of esophageal squamous cell carcinoma via regulation of miR-7/HOXB13," *Cell Death & Disease*, vol. 9, 2018.

[30] M. Sang, L. Meng, Y. Sang et al., "Circular RNA cIRs-7 accelerates ESCC progression through acting as a miR-876-5p sponge to enhance MAGE-A family expression," *Cancer Letters*, vol. 426, pp. 37–46, 2018.

[31] D. Moher, A. Liberati, J. Tetzlaff, and D. G. A. Altman, "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement," *BMJ*, vol. 339, no. 1, Article ID b2535, 2009.

[32] A. Stang, "Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses," *European Journal of Epidemiology*, vol. 25, no. 9, pp. 603–605, 2010.

[33] L. Xu, Y. Zhang, J. Tang et al., "The prognostic value and regulatory mechanisms of microRNA-145 in various tumors: a systematic review and meta-analysis of 50 studies," *Cancer Epidemiology Biomarkers & Prevention*, vol. 28, no. 5, pp. 867–881, 2019.

[34] J. F. Tierney, L. A. Stewart, D. Ghersi, S. Burdett, and J. P. T. Higgins, "Quantifying heterogeneity in a meta-analysis," *Statistics in Medicine*, vol. 21, no. 11, pp. 1539–1558, 2002.

[35] R. DerSimonian and N. Laird, "Meta-analysis in clinical trials," *Controlled Clinical Trials*, vol. 7, no. 3, pp. 177–188, 1986.

[36] N. Mantel and W. Haenszel, "Statistical aspects of the analysis of data from retrospective studies of disease," *Journal of the National Cancer Institute*, vol. 22, no. 4, pp. 719–748, 1959.

[37] C. B. Begg and M. Mazumdar, "Operating characteristics of a rank correlation test for publication bias," *Biometrics*, vol. 50, no. 4, pp. 1088–1101, 1994.

[38] F. Bray, A. Jemal, N. Grey, J. Ferlay, and D. Forman, "Global cancer transitions according to the Human Development Index (2008–2030): a population-based study," *The Lancet Oncology*, vol. 13, no. 8, pp. 790–801, 2012.

[39] X. Huang, W. Zhang, and Z. Shao, "Prognostic and diagnostic significance of circRNAs expression in lung cancer," *Journal of Cellular Physiology*, vol. 234, no. 10, 2019.

[40] X. Li, M. He, J. Guo, and T. Cao, "Uregulation of circular RNA circ-EBBP2 predicts unfavorable prognosis and facilitates the progression of gastric cancer via miR-503/CACUL1 and miR-637/MMP-19 signaling," *Biochemical and Bio
dysregulated miR-671-5p/CDR1-AS/CDR1/VSNLI axis is involved in glioblastoma multiforme," *Oncotarget*, vol. 7, no. 4, pp. 4746–4759, 2016.

[50] T. Suto, T. Yokobori, R. Yajima et al., "MicroRNA-7 as a potential therapeutic target for aberrant NF-κB-driven distant metastasis of gastric cancer," *Journal of Experimental & Clinical Cancer Research*, vol. 38, no. 1, p. 55, 2019.

[51] L. Jiang, X. Liu, Z. Chen et al., "MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells," *Biochemical Journal*, vol. 432, no. 1, pp. 199–207, 2010.

[52] X. Kong, G. Li, Y. Yuan et al., "MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression," *PLOS One*, vol. 7, no. 8, Article ID e41523, 2012.

[53] S. D. N. Reddy, K. Ohshiro, S. K. Rayala, and R. Kumar, "MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions," *Cancer Research*, vol. 68, no. 20, pp. 8195–8200, 2008.

[54] W. R. Jeck, J. A. Sorrentino, K. Wang et al., "Circular RNAs are abundant, conserved, and associated with ALU repeats," *RNA*, vol. 19, no. 2, pp. 141–157, 2013.

[55] W.-B. Yin, M.-G. Yan, X. Fang, J.-J. Guo, W. Xiong, and R.-P. Zhang, "Circulating circular RNA hsa_circ_0001785 acts as a diagnostic biomarker for breast cancer detection," *Clinica Chimica Acta*, vol. 487, pp. 363–368, 2018.

[56] L. Li, S. Chen, H. Chen et al., "Using circular RNA as a novel type of biomarker in the screening of gastric cancer," *Clinica Chimica Acta*, vol. 444, pp. 132–136, 2015.

[57] D. Fanale, S. Taverna, A. Russo, and V. Bazan, "Circular RNA in exosomes," *Advances in Experimental Medicine and Biology*, vol. 1087, pp. 109–117, 2018.